AGENDA – Pokani

AGENDA

The genetic landscape and molecular diagnostics in AML

Fred Hutchinson Cancer Research Canter, Seattle

How do I treat AML patients eligible for intensive chemotherapy?

Duke Blood Cancer Center, Durham

How do I Manage AML Patients Receiving HMA/venetoclax or LoDAC/venetoclax?

The University of Pennsylvania

How do I Use MRD data to Guide Post-remission Therapy?

Mayo Clinic, Phoenix, Arizona, USA

How do I treat relapsed/refractory patients without a FLT3 or IDH mutation?

University of California

Second generation FLT3 inhibitors in relapsed/refractory and treatment-naive AML

The University of Pennsylvania

What is the role of the IDH inhibitors in relapsed/refractory and treatment naive AML

Memorial Sloan Kettering Cancer Center, New York

How do I use maintenance therapy in AML?

Weill Cornell University Medical College, New York, USA

How do I treat therapy-related AML?

City of Hope, California

How do I treat AML following an antecedent myeloid neoplasm?

University of Miami, Florida

How Do We Approach post MPN-AML patients?

Anderson Cancer Center, Houston, Texas

Can we overcome resistance in TP53 mutated AML?

Moffitt Cancer Center, Tampa

Targeting KMT2A and NPM1 with Menin inhibitors

Roswell Park Comprehensive Cancer Centre, New York

Immune Based Therapies in AML

MD Anderson Cancer Center, Houston, Texas